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abstract
Attention Deficit Hyperactivity Disorder (ADHD) is 
a neurobehavioural disorder found more commonly, but 
not exclusively, in school-age children. The hallmarks 
of the condition are inattention and hyperactivity/
impulsivity, which often go together. Although the term 
ADHD was coined relatively recently, ADHD has in fact 
been described as early as 1902. This review article 
will go through the most important historical aspects 
of the condition, and will also give an account of what 
is known about the aetiology of ADHD. The diagnostic 
criteria issued by the American Psychiatric Association 
in DSM-5, have been last updated in May 2013. This 
article will highlight the differences between DSM-5 and 
the previous version, DSM-IV-TR, and will also touch 
upon the latest developments in electroencephalography-
based investigations and imaging studies for ADHD. 
Although the condition cannot be cured, symptoms can 
be managed using various modalities such as behaviour 
intervention strategies and medication, such that the 
individual affected by ADHD can have the least possible 
disruption to social and academic functioning.
abbrevIatIons
ADHD – Attention Deficit Hyperactivity Disorder
DSM-5 – Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition
CDC – Centers for Disease Control and Prevention (US)
FDA – Food and Drug Administration
IntroductIon
Attention Deficit Hyperactivity Disorder (ADHD) 
is characterized by inattention, hyperactivity and 
impulsivity. It is a common and widely studied 
neurobehavioural disorder in school age children 
(Desmond, 2011). Some leading figures in the ADHD 
field have questioned whether ADHD, as it is being 
diagnosed today, actually does exist or whether it has 
become convenient to merely attribute behavioural 
difficulties to ADHD, resulting in overdiagnosis and 
inappropriate treatment of children.
hIstory 
The recognition of ADHD as a neurobehavioural 
disorder goes back over one hundred years, although 
the term ADHD was only coined in 1987. In 1902, Sir 
George Frederick Still (1868-1941) published a paper in 
The Lancet entitled, ‘Some abnormal psychical conditions 
in children: the Goulstonian lectures’. He described 
43 children who he had come across in his practice, 
who displayed behavioural features that could today be 
attributed to ADHD, such as poor attention, difficulty 
with self-regulation, emotional lability, disinhibited 
behaviour and normal cognitive functioning. Still chose 
to call this constellation of features, ‘Disorders of Moral 
Control’.
In 1917, the Romanian psychiatrist and neurologist, 
Constantin von Economo (1876-1931) described the 
encephalitis epidemic that was rampant between 1915 
and 1926 mainly in Europe and North America. This 
atypical form of encephalitis was known as encephalitis 
lethargica or Von Economo disease. Adult survivors 
often developed a parkinsonian-like post-encephalitic 
phase, sometimes after a latent period of several years, 
while children tended to develop behavioural difficulties, 
including overactivity, impulsivity and poor coordination 
(Arnold, 1995; Wender, 1995). This was called minimal 
brain dysfunction-like behaviour. Von Economo also 
described the histology and showed that encephalitis 
lethargica mainly affected the dopamine-rich areas of 
the brain, often with autoantibodies against human 
basal ganglia antigens. Nowadays, it is widely known 
and accepted that the dopamine pathway is affected in 
ADHD sufferers (Dawei et al., 2006).
In 1923, Franklin G. Ebaugh, an American physician, 
published a paper in the American Journal of Diseases of 
Children entitled ‘Neuropsychiatric sequelae of acute 
epidemic encephalitis in children’. Ebaugh was the 
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first to realise that ADHD could be the result of brain 
injury in children who had no prior behavioural issues 
(Spencer, 2007).
In 1937, Charles Bradley (1902-1979), a Rhode 
Island paediatrician, made an unexpected discovery when 
he realised that children who had behavioural difficulties 
and poor academic performance, showed a marked 
improvement when given benzedrine, a stimulant. At 
the time, Bradley was carrying out diagnostic procedures 
called pneumoencephalographies, where most of the 
patient’s cerebrospinal fluid (CSF) was drained to be 
replaced by air or helium, thereby obtaining a clearer 
X-ray image of the brain. Benzedrine was administered 
so as to increase CSF production and reduce the severe 
headaches that were so common after this procedure. 
In 1936, benzedrine was FDA-approved as treatment for 
ADHD symptoms (CDC, 2014).
epIdemIology and aetIology
The American Psychiatric Association reports that 
5% of children have ADHD (APA, DSM-5, 2013). 
However, the CDC data obtained from the National 
Survey of Children’s Health which has been carried out 
every 4 years from 2003, quotes a much higher figure of 
around 11% of children aged 4-17 years. The diagnosis 
is on the increase, 5% per year increase over the period 
2003–2011. It is more common in boys (13.2% in 
boys, 5.6% in girls), with an average age at diagnosis of 
7 years (CDC, 2013). Approximately half of all children 
with ADHD go on to have symptoms in adulthood. The 
National Resource Centre on AD/HD (2014), quotes a 
prevalence rate of ADHD in adults in the United States, 
of 4.4%.
It is widely accepted that ADHD is a neurobiologic 
disorder primarily affecting the dopamine and 
noradrenaline pathways in the brain (Medscape 
Pediatrics, n.d.), with a strong genetic influence (Ross, 
2012). There is a 50% concordance in first degree 
relatives. Several other factors have been attributed to the 
aetiology of ADHD, especially antenatal complications, 
prematurity and low birth weight, as well as tobacco 
smoking and alcohol consumption by the mother during 
pregnancy. Postnatal injury to the prefrontal areas of the 
brain has also been implicated (CDC, 2014).  It is thought 
that azo dyes, a type of synthetic food colouring, may have 
an impact on ADHD behaviours, probably by causing zinc 
deficiency and, thereby, interfering with the processes 
that eliminate mercury from the body (Dufault, 2009). 
To this effect, in July 2008, the European Union ruled 
that as of July 2010, apart from the relevant E number for 
the particular azo dye, the product must clearly display 
the phrase ‘may have an adverse effect on activity and 
attention in children’ (McBurney, 2011). Studies show no 
cause-effect relationship between sucrose ingestion and 
ADHD (Benton, 2008). However, an important point of 
consideration is that the sugar that is found ubiquitously 
in processed foods, particularly sweets and sugary drinks, 
is not sucrose but high fructose corn syrup (HFCS), and 
therefore, one can only conclude that a high-sucrose diet, 
not a high-sugar diet, does not cause ADHD. HFCS is often 
contaminated with mercury while it is produced, and 
further studies are needed to determine whether ingestion 
of HFCS is associated with ADHD (Dufault, 2009).
Exposure to heavy metals from the diet, particularly 
in the prenatal period and in the first few years of life, 
has an impact on ADHD. High body lead levels have long 
been known to cause neurobehavioral problems. Mercury 
exists in two main forms – the inorganic form that is found 
mainly in soil and water, and the organomercurials. The 
earliest evidence that mercury is toxic to humans dates 
from the 1950s-1960s when mercury-containing industrial 
effluent from acetaldehyde production, was discharged 
into Minimata Bay, Japan. The result was that people 
who consumed fish and seafood caught from the bay 
in question, developed neurological and developmental 
disorders. Methylmercury is an organic type of mercury 
that is concentrated in the aquatic food chain. Current 
FDA recommendations for pregnant women are to eat no 
more than two portions (12 ounces or 340g) of fish or 
seafood per week, and to choose fish that is relatively low 
in mercury, such as salmon, shrimp, pollock, canned light 
tuna and catfish. Due to their high mercury levels, shark, 
swordfish, king mackerel and tilefish should be avoided 
in pregnancy, so as to reduce exposure of the foetus to 
the heavy metal (FDA, 2004). 
Ethylmercury is another type of organic mercury, 
which however, appears to be less toxic to humans 
because it is metabolized and excreted differently to 
methylmercury. The main way in which humans are 
exposed to ethylmercury is through thiomersal, a 
preservative used first in the 1930s in biological products 
and some vaccines, but is now being phased out (FDA, 
2014). Thiomersal is still used in some multi-dose vials of 
inactivated influenza vaccine, but these are not imported 
in Malta and Gozo. As a result, all vaccines that are 
administered to children and pregnant women locally, 
are thiomersal-free or have a trace amount of thiomersal 
(<1microgram of mercury per dose).
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An interesting study that looked at the effects of 
mercury (from seafood) and lead (from gunshot pellets 
in birds and animals that are hunted for food) in Arctic 
Canada, showed that prenatal methylmercury exposure 
was linked to ADHD symptoms later in childhood, and 
that even a low lead level in childhood, is associated with 
ADHD (Boucher et al., 2012). 
dIagnosIs 
The fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), was issued by 
the American Psychiatric Association on 18th May 
2013 (APA, DSM-5, 2013). This replaced the previous 
DSM-IV-TR version. Table 1 highlights the changes in 
DSM-5 as compared to the previous edition. DSM uses 
the term ADHD, which is then subclassified into three 
presentations. The World Health Organization’s (WHO) 
International Statistical Classification of Diseases and 
Related Health Problems, 10th revision (ICD-10), in use 
since 1992, uses the term Hyperkinetic Disorder (HKD), 
with ADHD listed as a subcategory. ICD-10 will be 
superseded by ICD-11 in 2017. The DSM-5 criteria cater 
for adolescents and adults who have ADHD symptoms, 
which were not necessarily present in early childhood.
The diagnosis of ADHD is made by obtaining a 
detailed history from the parents, caregivers and teachers, 
and from the adolescent or adult patient. Behaviour 
rating scales, of which there are several available, are 
the main tools used to diagnose ADHD. Conners 
Rating scale, perhaps the most well known and widely 
used system, was devised by Carmen Keith Conners, 
a clinical psychologist who set up the ADHD program 
at Duke University, USA. This behaviour rating scale 
is currently in its third edition, Conners 3TM, to reflect 
DSM-IV-TR (2000)
Criteria now obsolete
DSM-5 (2013)
Criteria currently in use
ADHD listed under Disruptive Behavior Disorders ADHD listed under Neurodevelopmental Disorders
9 inattentive & 9 hyperactive-impulsive behaviours listed
examples given of behaviours expected in older child/
adolescent
6 symptoms needed to make a diagnosis
only 5 symptoms needed to make a diagnosis in >17 
years & adults
symptoms which are not in-keeping with child’s developmental level, present for 6 months or longer
symptoms must be present and cause impairment by 7 
years of age
symptoms must be present, but not necessarily cause 
impairment, by 12 years of age
symptoms cause some impairment in at least 2 settings several symptoms present in two or more settings
‘clinically significant impairment in social, academic or 
occupational functioning’
‘clear evidence that the symptoms interfere with, or 
reduce the quality of, social, academic, or occupational 
functioning’
3 subtypes:
Predominantly Inattentive Type
Predominantly Hyperactive-Impulsive Type
Combined Type
3 presentations:
Predominantly Inattentive Presentation
Predominantly Hyperactive-Impulsive Presentation
Combined Presentation
Can change from one to the other
If symptoms no longer fulfill diagnostic criteria, specify in ‘Partial Remission’
ADHD diagnosis made as mild, moderate or severe
ADHD cannot be diagnosed with Autistic Spectrum 
Disorder
Recognizes that ADHD can coexist with Autistic Spectrum 
Disorder
Table 1: ADHD diagnostic criteria, main differences between DSM-IV-TR and DSM-5
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the new DSM-5 criteria (Conners, 2013). Perhaps the 
major flaw of such a behaviour rating scale, which is 
in the form of a questionnaire that requires the person 
to rate the particular behaviour on a score from 1-5, 
is its subjectivity. A physical examination, including a 
vision and hearing test should be done to exclude other 
conditions. Body lead levels are only indicated if the 
history is suggestive of a high lead exposure. 
Imaging studies, including single-photon emission 
computed tomography (SPECT), positron emission 
tomography (PET), and functional magnetic resonance 
imaging (fMRI), have shown that there is about a 3 
year delay in brain maturation and some differences in 
brain activity in children with ADHD when compared 
to controls (Watson, 2013).  SPECT, a costly procedure, 
which uses an injectable radioactive substance to measure 
blood flow and brain activity, is not yet FDA-approved 
for ADHD diagnosis. In July 2013, FDA approved the 
first brain imaging test for ADHD diagnosis in patients 
of 6-17 years of age. This Neuropsychiatric EEG-Based 
Assessment Aid (NEBA) System is a 15 minute EEG-
based test which measures the theta-beta ratio of brain 
waves emitted (FDA, 2013). This ratio is known to 
be higher in individuals with ADHD as compared to 
controls. The procedure, pioneered by Howard Merry, has 
come under criticism because of the way FDA approved 
the test based only on Merry’s study of 275 individuals, 
and also because of the cost involved to carry out this 
test (Brauser, 2014). NEBA is not a stand-alone diagnostic 
test for ADHD, but should be used in conjunction with 
the standard behaviour rating scales and fulfilment of 
DSM-5 criteria. It remains to be seen whether NEBA is 
useful in distinguishing ADHD from bipolar disorder in 
adolescents, a distinction that can be very difficult to 
make accurately.
It is imperative that a diagnosis of ADHD is made 
accurately by stringent use of the DSM 5 criteria. 
Otherwise, we run the risk of overdiagnosing and 
overtreating patients. Some leading figures in the ADHD 
field have questioned whether ADHD really does exist. 
To cite one example, reference is made to an opinion 
piece that was published on Time on 14th March 2014 
by Dr Richard Saul, a fellow with the American Academy 
of Paediatrics and an associate fellow of the American 
Academy of Neurology. ‘I’ve come to believe based on 
decades of treating patients that ADHD — as currently 
defined by the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) and as understood in the public 
imagination — does not exist’ (Saul, 2014). 
management
Apart from the use of medications, the management 
of ADHD involves behavioural intervention strategies and 
educating the family on how to deal with the condition. 
It also has implications on schooling - some children 
with ADHD may benefit from the help of a Learning 
Support Assistant. 
The Feingold® diet is an elimination diet that is 
free from dyes, artificial flavours, sweeteners and 
preservatives, and can be used both as a diagnostic tool 
to determine whether any dietary factors are negatively 
affecting ADHD behaviours, as well as a treatment 
modality for ADHD. Using a double-blind randomised 
controlled trial, Rucklidge et al., (2014), showed that a 
micronutrient supplement consisting of various vitamins 
and minerals may have some efficacy in managing adults 
with ADHD.
Drugs are FDA-approved from 6 years of age, and 
once started, it is recommended to stop the treatment 
for a couple of weeks, usually in the summer, so as to 
determine whether the patient still requires medication 
or not. Other factors to keep in mind are adverse drug 
effects, drug interactions, co-morbid conditions and 
parent and child-preferences.
The two main groups of drugs for ADHD treatment 
are the stimulants and non-stimulants. The drugs that are 
available locally are the stimulants Ritalin® and Concerta® 
(both methylphenidate) and the non-stimulant Strattera® 
(atomoxetine).
Methylphenidate is a dopamine-reuptake inhibitor, 
and so increases extracellular dopamine in the striatium. 
Ritalin® is an immediate-release form with a duration 
of action of 3-4 hours (SPC Ritalin®, 2013), whereas 
Concerta®, which is intermediate-release with a duration 
of action of up to 12 hours (SPC Concerta®, 2014), has 
the advantage of once daily dosing. The dose is increased 
in a stepwise fashion over a 4 week period. Around 75% 
of patients respond to treatment, while the remainder 
either show no improvement or have side effects which 
necessitate stopping the drug. The most common side 
effects are reduced appetite, transient weight loss, 
irritability and sleep disturbance. In January 2009, 
the European Medicines Agency (EMEA) issued some 
recommendations on the safe use of methylphenidate 
(EMEA, 2009). Because of the cardiovascular and 
cerebrovascular risks, all patients should have their 
blood pressure and heart rate measured before starting 
treatment, and every 3 months while on medication. 
Prior to starting methylphenidate, one should ask about 
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a family history of cardiovascular disorders, and in those 
patients with a positive family or personal history or 
an abnormal cardiovascular examination, an ECG and 
cardiology consultation would be warranted. The patient’s 
height and weight should be measured, and one must 
look out for the development of psychiatric disorders.
The use of methylphenidate locally has shown a 4 
fold increase since the year 2000, as shown in Figure 1.
Strattera® is a selective noradrenaline reuptake 
inhibitor, with a duration of action of 12 hours. It is 
usually given as a single daily dose in the morning, and 
the capsule has to be swallowed whole. The most common 
side effects are sleep disturbances, fatigue, nervousness, 
dry mouth and stomach upset.  Suicidal ideation (0.4% in 
Strattera-treated group as compared to 0% in the placebo 
group); severe liver injury, including hepatic failure, 
which was only picked up in post-marketing surveillance 
of the drug; and sudden deaths in children who had an 
underlying structural cardiac abnormality, have been 
reported (SPC Strattera, 2013). 
Figure 1: Number of patients started on Ritalin® in Malta over the period 2000-2013
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assocIated ImpaIrments
People who suffer from ADHD, may also have 
associated impairments. The most common problems 
are difficulty in peer-relationships and an increased 
risk of injuries. An associated learning disorder 
is found in approximately half of 6-11 year olds 
with ADHD. Data from the CDC National Health 
Interview Survey (2008) shows that in the US over 
the period 2004-2006, 5% of children aged 6-17 
years had ADHD without a learning disability, 5% 
had a learning disability without ADHD, and 4% had 
both conditions. Oppositional Defiant Disorder and 
Conduct Disorder are less common. 
The ADHD Family Support Group Malta is a 
non-governmental organization which holds monthly 
meetings for families of ADHD-sufferers as well as the 
public in general.  
conclusIon
Over the past years, ADHD has been studied 
closely and much research has been carried out, 
particularly to elucidate the aetiology of the condition, 
to make a more accurate and timely diagnosis, and for 
effective treatments to be made available. However, 
much still remains to be known.
The Journal of the Malta College of Family Doctors  VOLUME 03 issUE 03 DEcEMbEr 2014  21
reference
American Psychiatric Association, 2013. Diagnostic and Statistical Manual of 
Mental Disorders, Fifth edition: DSM-5. [pdf] Vancouver: American Psychiatric 
Association. Available at: <http://www.DSM5.org> [Accessed 19 April 
2014].
American Psychiatric Association, 2013. DSM-5 Attention Deficit/Hyperactivity 
Disorder Fact Sheet. [pdf] Vancouver: American Psychiatric Association. 
Available at: <http://www.dsm5.org/Documents/ADHD%20Fact%20Sheet.
pdf> [Accessed 19 April 2014].
Armstrong, T., 1996. ADD: Does It Really Exist? [online] Available at: <http://
education.jhu.edu/PD/newhorizons/Exceptional%20Learners/ADD%20
ADHD/Articles/ADD%20Does%20it%20Exist/> [Accessed 19 April 2014].
Arnold, L.E. and Jensen, P.S., 1995. Attention Deficit Disorders. In: H.I. Kaplan 
and B.J. Sadock, eds. 1995. Comprehensive Textbook of Psychiatry, vol 2. 6th 
edition. Baltimore, Maryland. Williams & Wilkins. 
Benton, D., 2008. Sucrose and Behavioral Problems. Critical Reviews in Food Science 
and Nutrition, 48(5), pp.385-401.
Boucher, O., et al., 2012. Prenatal Methylmercury, Postnatal Lead Exposure, and 
Evidence of Attention Deficit/Hyperactivity Disorder among Inuit Children in 
Arctic Quebec. Environmental Health Perspectives, 120(10), pp.1456-1461.
Brauser, D., 2014. Mixed Reaction to FDA Approval of ADHD Brain-Wave 
Test. Medscape, [online] Available at: <http://www.medscape.com/
viewarticle/809079> [Accessed 21 April 2014].
Centers for Disease Control and Prevention, 2014. Attention Deficit / Hyperactivity 
Disorder (ADHD). [pdf] Atlanta: CDC. Available at: <http://www.cdc.gov/
ncbddd/adhd/facts.html> [Accessed 20 April 2014].
Conners, C. K., 2013. Conners 3rd Edition TM. Multi-Health Systems. [online] 
Available at: <http://www.mhs.com/product.aspx?gr=edu&id=overview&p
rod=conners3> [Accessed 19 April 2014].
Cunningham, N.R. and Jensen, P., 2011. Attention-Deficit/Hyperactivity Disorder. 
In: R.M. Kliegman et al., eds. 2011. Nelson Textbook of Pediatrics. 19th edition. 
Philadelphia: Elsevier Saunders. Ch.30.
Dawei, L., et al., 2006. Meta-analysis shows significant association between 
dopamine system genes and attention deficit hyperactivity disorder (ADHD). 
Human Molecular Genetics, [online] Available at: <http://hmg.oxfordjournals.
org/content/15/14/2276.long> [Accessed 28th October 2014].
Dufault, R., et al., 2009. Mercury exposure, nutritional deficiencies and metabolic 
disruptions may affect learning in children. Behavioral and Brain Functions, 
[online] Available at: <http://www.behavioralandbrainfunctions.com/
content/5/1/44> [Accessed 30 June 2014].
Eli Lilly and Company (Ireland) Limited, 2013. Summary of Product Characteristics, 
Strattera®. [pdf] Dublin: Eli Lilly and Company (Ireland) Limited. Available 
at: <http://www.medicines.org.uk/emc/medicine/14482/SPC/Strattera+1
0mg,+18mg,+25mg,+40mg,+60mg,+80mg+or+100mg+hard+capsul
es./> [Accessed 25 April 2014].
European Medicines Agency, 2009. European Medicines Agency makes 
recommendations for safer use of Ritalin and other methylphenidate-containing 
medicines in the EU. Press release, 22 January 2009.
FDA, U.S. Food and Drug Administration, 2004. What You Need to Know About 
Mercury in Fish and Shellfish (Brochure). [pdf] Silver Spring, Maryland: 
FDA. Available at: <http://www.fda.gov/food/resourcesforyou/consumers/
ucm110591.htm> [Accessed 30 June 2014].
FDA, U.S. Food and Drug Administration, 2013. FDA permits marketing of first brain 
wave test to help assess children and teens with ADHD. Press release, 15 July 
2013. 
FDA, U.S. Food and Drug Administration, 2014. Thimerosal in Vaccines. 
[pdf] Silver Spring, Maryland: FDA. Available at: <http://www.fda.gov/
biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228> 
[Accessed 21 April 2014].
Feingold® Association of the United States, 2013. [online] Available at: <http://
www.feingold.org/what.php> [Accessed 30 June 2014].
Janssen-Cilag Ltd., 2014. Summary of Product Characteristics, Concerta®. [pdf] High 
Wycombe, Bucks: Janssen-Cilag Ltd. Available at: 
<https://www.medicines.org.uk/emc/medicine/8382/SPC/
Concerta+XL+18+mg+-+36+mg+prolonged+release+tablets/> 
[Accessed 25 April 2014].
Kelly, A.M., Margulies, D.S. and Castellanos, F.X., 2007. Recent advances 
in structural and functional brain imaging studies of attention-deficit/
hyperactivity disorder. Current Psychiatry Reports, [e-journal and in print] 
9(5). Abstract only. Available through: PubMed.gov website <http://www.
ncbi.nlm.nih.gov/pubmed/17915080> [Accessed 15 April 2014].
Lawton, G., 2014. A Musing Pediatrician. My Own Private A.D.H.D. Conspiracy 
Theory. Medscape [online] Available at: <http://boards.medscape.com/forum
s/?128@@.2a5c1c0f!comment=1> [Accessed 19 April 2014].
McBurney, M., 2011. ADHD, Medication risks, and Labeling of Azo Dyes. [online] 
Available at: <http://www.dsm.com/campaigns/talkingnutrition/en_US/
talkingnutrition-dsm-com/2011/12/20111213azo-dyes.html> [Accessed 19 
April 2014].
Medscape Pediatrics, n.d. Part 1. ADHD: Recent Advances in Diagnosis and Treatment. 
[online] Available at: <http://www.medscape.org/viewarticle/443113> 
[Accessed 20 April 2014].
National Resource Center on AD/HD: A Program of CHADD, 2014. ADHD Data 
and Statistics. Lanham, Maryland: National Resource Centre on AD/HD.
Novartis Pharmaceuticals UK Ltd, 2013. Summary of Product Characteristics, 
Ritalin®. [pdf] Surrey: Novartis Pharmaceuticals UK Ltd. Available at: <http://
www.medicines.org.uk/emc/medicine/1316/SPC/ritalin/> [Accessed 25 April 
2014].
Pastor, P.N. and Reuben, C.A., 2008. Diagnosed Attention Deficit Hyperactivity 
Disorder and Learning Disability: United States, 2004-2006. Washington: 
National Center for Health Statistics. Vital and Health Statistics. 
Porter, E., 2012. Conners Scale for Assessing ADHD. [online] Available at: <http://
www.healthline.com/health/adhd/conners-scale#1> [Accessed 22 April 
2014]. 
Ross, R.G., 2012. Advances in the Genetics of ADHD. The American Journal of 
Psychiatry, [online] Available at: <http://www.ajp.psychiatryonline.org/article.
aspx?articleid=483676> [Accessed 22 April 2014].
Rucklidge, J., et al., 2014. Vitamin-mineral treatment of attention-deficit 
hyperactivity disorder in adults: double-blind randomised placebo-controlled 
trial. The British Journal of Psychiatry, [online]. Abstract only. Available at: 
<http://bjp.rcpsych.org/content/204/4/306.abstract> [Accessed 30 June 
2014].
Saul, R., 2014. Doctor: ADHD Does Not Exist. Time. [online] Available at: <http://
time.com/25370/doctor-adhd-does-not-exist/> [Accessed 19 April 2014].
Spencer, T.J., Biederman, J. and Mick, E., 2007. Attention-Deficit/Hyperactivity 
Disorder: Diagnosis, Lifespan, Comorbidities, and Neurobiology. Journal of 
Pediatric Psychology 32(6) pp.631-642.
Watson, S., 2013. Worth 1,000 Words: What a Brain Scan Reveals About ADHD. 
[online] Available at: <http://www.healthline.com/health-slideshow/brain-
scans-adhd#promoSlide> [Accessed 22 April 2014].
Wender, P.H., 1995. Attention Deficit Hyperactivity Disorder in Adults. New York: 
Oxford University Press. pp.80-81.
Wender, P.H., Wolf, L.E. and Wasserstein J., 2001. Adults with ADHD: an Overview. 
Annals of the New York Academy of Sciences, 931, pp.1-16. 
Dr Christine GALEA 
MD, MRCPCH
Resident Specialist, Department of Paediatrics, 
Mater Dei Hospital
Email: christine.a.galea@gov.mt
Dr Christopher ScIBerraS 
MD, MRCPCH, MRCP(UK), MSc.Comm. Paeds 
(Warwick), DCH (Dublin), Cert. Dev. Paeds. (London) 
Consultant Paediatrician, Community 
Paediatrics and Disability Services, Department 
of Paediatrics, Mater Dei Hospital
Dr Marthese GALEA 
MD, MRCPCH
Resident Specialist, Department of Paediatrics, 
Mater Dei Hospital
